Windows App SDK (formerly Project Reunion) is a set of libraries, frameworks, components, and tools that you can use in your apps to access powerful Windows platform functionality from all kinds of ...

BNP Paribas Exane analyst Peter Verdult initiated coverage of GSK (GSK) with a Neutral rating and $35.25 price target Discover outperforming stocks and invest smarter with Top Smart Score Stocks.

In spring 2021, my family sold a big lump of GSK shares. Four years later, we have no regrets. Indeed, with the GSK share price stumbling, we may buy soon. When investing, your capital is at risk.

Editor's take: The list of deprecated features in the Windows ecosystem continues to grow, even as millions still rely on them daily. Occasionally, Microsoft has to tap the brakes on its phase-out ...

The NCAA informed him Tuesday that the correct and current WMU logo would be in place in time for Thursday's national semifinals. It actually was fixed as of Tuesday night. "Yesterday, we noted an ...

Big pharmaceutical companies have been making deals for technologies that could help them get their molecules through this protective membrane and now GSK is joining in, striking up an alliance ...

SEONGNAM, South Korea I April 7, 2025 I ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, ...

A BELOVED fitness and sporting goods store has closed its doors after nearly three decades serving fitness enthusiasts in Colchester. Heroes Fitness, known for its fitness supplements and ...

As part of the agreement, ABL Bio will transfer Grabody-B-related technology and know-how to GSK, while GSK will assume responsibility for preclinical and clinical development, manufacturing ...

GSK and ABL Bio have entered into an agreement worth over £2bn to develop new drugs for neurodegenerative diseases. The global licensing deal will allow GSK to use ABL Bio’s blood-brain barrier (BBB) ...

GSK is betting potentially billions of dollars that a smaller drug company’s technology can help create new treatments for brain-corroding diseases. Through a licensing deal announced Sunday, GSK has ...

South Korean clinical-stage biotech ABL Bio (Kosdaq: 298380) on Sunday announced a worldwide licensing agreement enabling GSK (LSE: GSK) to develop novel medicines for neurodegenerative diseases by ...